Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion
NASDAQ:VERU

Veru 4/1/2024 Earnings Report

Veru logo
$2.35 +0.13 (+5.86%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$2.32 -0.03 (-1.32%)
As of 05/22/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Veru EPS Results

Actual EPS
-$0.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Veru Revenue Results

Actual Revenue
$2.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Veru Announcement Details

Quarter
Date
4/1/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Veru's Q3 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Veru Earnings Headlines

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/veru-inc-veru-q2-2026-230324085.html
Transcript: Veru Q2 2026 Earnings Conference Call
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/transcript-veru-q2-2026-earnings-125034404.html
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 12th.tc pixel
May 24 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Veru (VERU) Q2 2026 Earnings Transcript
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/veru-veru-q2-2026-earnings-184803348.html
Veru outlines Q1 2027 interim readout for 36-week enobosarm plateau analysis
May 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/veru-outlines-q1-2027-interim-readout-for-36-week-enobosarm-plateau-analysis/ar-AA236PZB
Veru Inc. Earnings Call Highlights Clinical Momentum
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/veru-inc-earnings-call-highlights-clinical-momentum?utm_source=marketbeat.com&utm_medium=referral
See More Veru Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email.

About Veru

Veru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses.

Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.

View Veru Profile
Earnings Tools